3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
59
Neoplasms
6
Neoplasm Metastasis
5
Melanoma
5
Carcinoma, Non-Small-Cell Lung
5
Colorectal Neoplasms
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Hereditary Sensory and Autonomic Neuropathies
3
Endometrial Neoplasms
3
Breast Diseases
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neuroblastoma
2
Multiple Endocrine Neoplasia Type 1
2
Lymphoma
2
Lung Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Teratoma
1
Stomach Neoplasms
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Solid Tumors
1
Rhabdomyosarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Osteitis Deformans
1
Neoplasms, Germ Cell and Embryonal
1
Interventions
pembrolizumab
15
Pemetrexed
15
Cisplatin
12
Nivolumab
9
Carboplatin
8
Ipilimumab
7
tazemetostat
3
fludarabine
3
anetumab ravtansine
3
Cyclophosphamide
3
spartalizumab
2
budigalimab
2
belinostat
2
atezolizumab
2
amatuximab
2
Vinorelbine
2
Paclitaxel
2
Gemcitabine
2
Docetaxel
2
venetoclax
1
vandetanib
1
trametinib
1
tocilizumab
1
tislelizumab
1
sotorasib
1
ruxolitinib
1
rovalpituzumab tesirine
1
ribociclib
1
rebastinib
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mesothelioma
×
ribociclib
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts